A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for Treatment of CD25 Positive Cutaneous T-Cell Lymphomas
Phase: PHASE2
Conditions: Lymphoma, T-Cell, Cutaneous
Sponsor: National Cancer Institute (NCI)

04-C-0142. AM J
Sarita Thomas/ OPS
8-15-11